Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa Abstract #2062

Introduction: LANRELO7484 is an ongoing, observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) in South Africa (SA).
Aim(s): The study aims to evaluate patients’ level of satisfaction and symptomatic response with diarrhoea and/or flushing when treated with Lanreotide Autogel over a six-month period. Quality of life (QoL), exposure to treatment and safety of Lanreotide Autogel in patients with GEP-NET treated with Lanreotide Autogel are also being measured.
Materials and methods: This is a national, ongoing, multi-centre, prospective observational cohort study involving 11 oncology sites. The decision on treatment is made in accordance with routine clinical practice at the centre concerned. Patients are followed up for 6 months after commencing treatment with Lanreotide Autogel. The data is collected prospectively at a baseline visit, 3 months (3M) and 6 months (6M). The QoL data reported in this abstract is an interim analysis of the data available on the 7th of August 2017 for 23 patients.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Monique Nel

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores
Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Phan A, Beaumont J L, Liu Z, Choi S, ...